|
1
|
Jemal A, Murray T, Samuels A, Ghafoor A,
Ward E and Thun MJ: Cancer statistics, 2003. CA Cancer J Clin.
53:5–26. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pasetto LM, Jirillo A, Iadicicco G, Rossi
E, Paris MK and Monfardini S: FOLFOX versus FOLFIRI: a comparison
of regimens in the treatment of colorectal cancer metastases.
Anticancer Res. 25:563–576. 2005.PubMed/NCBI
|
|
3
|
Goldberg RM and Gill S: Recent phase III
trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy
for metastatic colorectal cancer. Cancer Chemother Pharmacol.
54(Suppl 1): S57–S64. 2004.PubMed/NCBI
|
|
4
|
Loeve F, van Ballegooijen M, Snel P and
Habbema JD: Colorectal cancer risk after colonoscopic polypectomy:
a population-based study and literature search. Eur J Cancer.
41:416–422. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Koehler A, Bataille F, Schmid C, Ruemmele
P, Waldeck A, Blaszyk H, Hartmann A, Hofstaedter F and Dietmaier W:
Gene expression profiling of colorectal cancer and metastases
divides tumours according to their clinicopathological stage. J
Pathol. 204:65–74. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kolonel LN, Altshuler D and Henderson BE:
The multiethnic cohort study: exploring genes, lifestyle and cancer
risk. Nat Rev Cancer. 4:519–527. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ohtsuka M, Ling H, Doki Y, Mori M and
Calin GA: MicroRNA processing and human cancer. J Clin Med.
4:1651–1667. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang J, Song YX, Ma B, Wang JJ, Sun JX,
Chen XW, Zhao JH, Yang YC and Wang ZN: Regulatory roles of
non-coding RNAs in colorectal cancer. Int J Mol Sci.
16:19886–19919. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Anwar SL and Lehmann U: MicroRNAs:
emerging novel clinical biomarkers for hepatocellular carcinomas. J
Clin Med. 4:1631–1650. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kedmi M, Sas-Chen A and Yarden Y:
MicroRNAs and growth factors: an alliance propelling tumor
progression. J Clin Med. 4:1578–1599. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Han F, He J, Li F, Yang J, Wei J, Cho WC
and Liu X: Emerging roles of nicroRNAs in EGFR-targeted therapies
for lung cancer. Biomed Res Int. 2015:6727592015. View Article : Google Scholar
|
|
12
|
Croner RS, Foertsch T, Brueckl WM,
Guenther K, Siebenhaar R, Stremmel C, Matzel KE, Papadopoulos T,
Kirchner T, Behrens J, et al: Common denominator genes that
distinguish colorectal carcinoma from normal mucosa. Int J
Colorectal Dis. 20:353–362. 2005. View Article : Google Scholar
|
|
13
|
Raetz EA and Moos PJ: Impact of microarray
technology in clinical oncology. Cancer Invest. 22:312–320. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chiu ST, Hsieh FJ, Chen SW, Chen CL, Shu
HF and Li H: Clinicopathologic correlation of up-regulated genes
identified using cDNA microarray and real-time reverse
transcription-PCR in human colorectal cancer. Cancer Epidemiol
Biomarkers Prev. 14:437–443. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nambiar PR, Nakanishi M, Gupta R, Cheung
E, Firouzi A, Ma XJ, Flynn C, Dong M, Guda K, Levine J, et al:
Genetic signatures of high- and low-risk aberrant crypt foci in a
mouse model of sporadic colon cancer. Cancer Res. 64:6394–6401.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mariadason JM, Arango D, Shi Q, Wilson AJ,
Corner GA, Nicholas C, Aranes MJ, Lesser M, Schwartz EL and
Augenlicht LH: Gene expression profiling-based prediction of
response of colon carcinoma cells to 5-fluorouracil and
camptothecin. Cancer Res. 63:8791–8812. 2003.PubMed/NCBI
|
|
17
|
Neviani P and Fabbri M: Exosomic microRNAs
in the tumor microenvironment. Front Med (Lausanne). 2:472015.
|
|
18
|
Eisinger F, Roussel C, Morère JF and
Viguier J: Cancer screening: reaching the limits or terra
incognita? Lessons from the EDIFICE surveys. Eur J Cancer Prev.
20(Suppl 1): S42–S44. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Peters U, Bien S and Zubair N: Genetic
architecture of colorectal cancer. Gut. 64:1623–1636. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ng EK, Chong WW, Jin H, Lam EK, Shin VY,
Yu J, Poon TC, Ng SS and Sung JJ: Differential expression of
microRNAs in plasma of colorectal cancer patients: a potential
marker for colorectal cancer screening. Gut. 58:1375–1381. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu CW, Ng SS, Dong YJ, Ng SC, Leung WW,
Lee CW, Wong YN, Chan FK, Yu J and Sung JJ: Detection of miR-92a
and miR-21 in stool samples as potential screening biomarkers for
colorectal cancer and polyps. Gut. 61:739–745. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schetter AJ, Leung SY, Sohn JJ, Zanetti
KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, et
al: MicroRNA expression profiles associated with prognosis and
therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ruddon R: Cancer Biology. Oxford
University Press; New York, NY: 2007
|
|
25
|
Corvinus FM, Orth C, Moriggl R, Tsareva
SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal
K, et al: Persistent STAT3 activation in colon cancer is associated
with enhanced cell proliferation and tumor growth. Neoplasia.
7:545–555. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chekulaeva M and Filipowicz W: Mechanisms
of miRNA-mediated post-transcriptional regulation in animal cells.
Curr Opin Cell Biol. 21:452–460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li J, Dong X, Wang Z and Wu J: MicroRNA-1
in cardiac Diseases and cancers. Korean J Physiol Pharmacol.
18:359–363. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Datta J, Kutay H, Nasser MW, Nuovo GJ,
Wang B, Majumder S, Liu CG, Volinia S, Croce CM, Schmittgen TD, et
al: Methylation mediated silencing of MicroRNA-1 gene and its role
in hepato-cellular carcinogenesis. Cancer Res. 68:5049–5058. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hirai H, Verma M, Watanabe S, Tastad C,
Asakura Y and Asakura A: MyoD regulates apoptosis of myoblasts
through microRNA-mediated downregulation of Pax3. J Cell Biol.
191:347–365. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nasser MW, Datta J, Nuovo G, Kutay H,
Motiwala T, Majumder S, Wang B, Suster S, Jacob ST and Ghoshal K:
Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression
of tumorigenic property of lung cancer cells and their
sensitization to doxorubicin-induced apoptosis by miR-1. J Biol
Chem. 283:33394–33405. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yoshino H, Chiyomaru T, Enokida H,
Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N and Nakagawa
M: The tumour-suppressive function of miR-1 and miR-133a targeting
TAGLN2 in bladder cancer. Br J Cancer. 104:808–818. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nohata N, Sone Y, Hanazawa T, Fuse M,
Kikkawa N, Yoshino H, Chiyomaru T, Kawakami K, Enokida H, Nakagawa
M, et al: miR-1 as a tumor suppressive microRNA targeting TAGLN2 in
head and neck squamous cell carcinoma. Oncotarget. 2:29–42. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li
D, Lai L and Jiang BH: MiR-145 directly targets p70S6K1 in cancer
cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res.
40:761–774. 2012. View Article : Google Scholar :
|
|
35
|
Götte M, Mohr C, Koo CY, Stock C, Vaske
AK, Viola M, Ibrahim SA, Peddibhotla S, Teng YH, Low JY, et al:
miR-145-dependent targeting of junctional adhesion molecule A and
modulation of fascin expression are associated with reduced breast
cancer cell motility and invasiveness. Oncogene. 29:6569–6580.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Akao Y, Nakagawa Y, Iio A and Naoe T: Role
of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia
Jurkat cells. Leuk Res. 33:1530–1538. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gao W, Yu Y, Cao H, Shen H, Li X, Pan S
and Shu Y: Deregulated expression of miR-21, miR-143 and miR-181a
in non small cell lung cancer is related to clinicopathologic
characteristics or patient prognosis. Biomed Pharmacother.
64:399–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Clapé C, Fritz V, Henriquet C, Apparailly
F, Fernandez PL, Iborra F, Avancès C, Villalba M, Culine S and
Fajas L: miR-143 interferes with ERK5 signaling, and abrogates
prostate cancer progression in mice. PLoS One. 4:e75422009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee NP, Poon RT, Shek FH, Ng IO and Luk
JM: Role of cadherin-17 in oncogenesis and potential therapeutic
implications in hepatocellular carcinoma. Biochim Biophys Acta.
1806:138–145. 2010.PubMed/NCBI
|
|
40
|
Liu LX, Lee NP, Chan VW, Xue W, Zender L,
Zhang C, Mao M, Dai H, Wang XL, Xu MZ, et al: Targeting cadherin-17
inactivates Wnt signaling and inhibits tumor growth in liver
carcinoma. Hepatology. 50:1453–1463. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ibrahim AF, Weirauch U, Thomas M,
Grünweller A, Hartmann RK and Aigner A: MicroRNA replacement
therapy for miR-145 and miR-33a is efficacious in a model of colon
carcinoma. Cancer Res. 71:5214–5224. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Grzybowska-Izydorczyk O and Smolewski P:
The role of the inhibitor of apoptosis protein (IAP) family in
hematological malignancies. Postepy Hig Med Dosw (Online).
62:55–63. 2008.In Polish.
|
|
43
|
Herman MD, Moche M, Flodin S, Welin M,
Trésaugues L, Johansson I, Nilsson M, Nordlund P and Nyman T:
Structures of BIR domains from human NAIP and cIAP2. Acta
Crystallogr Sect F Struct Biol Cryst Commun. 65:1091–1096. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Verhagen AM, Coulson EJ and Vaux DL:
Inhibitor of apoptosis proteins and their relatives: IAPs and other
BIRPs. Genome Biol. 2:reviews3009–reviews3009.10. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Davoodi J, Ghahremani MH, Es-Haghi A,
Mohammad-Gholi A and Mackenzie A: Neuronal apoptosis inhibitory
protein, NAIP, is an inhibitor of procaspase-9. Int J Biochem Cell
Biol. 42:958–964. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dubrez-Daloz L, Dupoux A and Cartier J:
IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle.
7:1036–1046. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Franchi L, Eigenbrod T, Munoz-Planillo R
and Nunez G: The inflammasome: a caspase-1-activation platform that
regulates immune responses and disease pathogenesis. Nat Immunol.
10:241–247. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Pekow JR, Dougherty U, Mustafi R, Zhu H,
Kocherginsky M, Rubin DT, Hanauer SB, Hart J, Chang EB, Fichera A,
et al: miR-143 and miR-145 are downregulated in ulcerative colitis:
putative regulators of inflammation and protooncogenes. Inflamm
Bowel Dis. 18:94–100. 2012. View Article : Google Scholar
|
